Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study To Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001 In Participants With Selected Proteinuric Glomerular Diseases

NCT05800873 is registered in ClinicalTrials.gov with Everest Medicines (China) Co.,Ltd. as lead sponsor.

NCT NCT05800873
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05800873 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study To Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001 In Participants With Selected Proteinuric Glomerular Diseases
Lead sponsor
Everest Medicines (China) Co.,Ltd.
Phase
Phase 1
Overall status
Completed
Start date
May 15, 2023
Completion date
July 27, 2026
Enrollment
31 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

primary membranous nephropathy